Some vaginal bacteria may weaken anti-HIV gel: study

June 1, 2017
HIV infecting a human cell. Credit: NIH

Some kinds of vaginal bacteria may interfere with a gel meant to curb the risk of contracting HIV, which infects more than one million women worldwide each year, researchers said Thursday.

The findings in the journal Science were based on a 2010 study of women in South Africa who used the microbicide drug tenofovir, in vaginal gel form, to assess how well it worked at preventing transmission of (HIV).

The drug has shown success in preventing HIV in high-risk men, but studies involving women have been "disappointing," said the report.

A 2010 randomized trial called CAPRISA 004 showed that , applied before and after sex, reduced HIV incidence by 39 percent.

Researchers examined a subset of women who were infected with HIV during the study, even though they used the gel regularly.

Women who became infected with HIV tended to have a dominant bacteria known as Gardnerella vaginalis, which "could rapidly metabolize and break down the active form of the drug," said the report.

Gardnerella vaginalis is associated with a condition known as bacterial vaginosis (BV).

BV is known to increase the risk of HIV because it increases inflammation, disrupts the vaginal wall and impairs wound-healing, and women from sub-Saharan Africa have high prevalence rates of BV, according to background information in the report.

Women with healthier vaginal bacterial compositions—those dominated by the bacteria Lactobacillus—showed three-fold higher protection against HIV than women with different dominant vaginal bacteria compositions.

An accompanying Perspective article in Science pointed out that the research sheds some light on the reasons for the trial's shortcomings, but fails to offer a solution.

Even if women were tested for vaginal , it remains unclear whether the microbiome could be changed to allow for better performance of the gel, since BV returns in nearly 60 percent of women one year after treatment, wrote Susan Tuddenham and Khalil G. Ghanem of the Johns Hopkins University School of Medicine.

In the meantime, the study serves as a reminder that "without a deeper understanding of the structure, function, and dynamics of the vaginal microbiome, successful interventions to optimize it and improve 's health will remain elusive."

Explore further: Vaginal bacteria can trigger recurrent UTIs, study shows

More information: N.R. Klatt el al., "Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women," Science (2017). science.sciencemag.org/cgi/doi … 1126/science.aai9383

S. Tuddenham el al., "A microbiome variable in the HIV-prevention equation," Science (2017). science.sciencemag.org/cgi/doi … 1126/science.aan6103

Related Stories

Vaginal bacteria can trigger recurrent UTIs, study shows

March 30, 2017
About half of all women will experience urinary tract infections in their lifetimes, and despite treatment, about a quarter will develop recurrent infections within six months of initial infection.

New evidence on why young women in South Africa are at high risk of HIV infection

July 18, 2016
Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, ...

Oral probiotics have no impact on vaginal health in pregnancy

November 1, 2016
(HealthDay)—For pregnant women, probiotics have no effect on vaginal health, according to a study published in the November issue of the American Journal of Obstetrics & Gynecology.

Certain species of vaginal bacteria can increase a woman's susceptibility to HIV

January 10, 2017
Specific bacteria living in the human vagina may play a previously unrecognized role in the sexual transmission of HIV. Ragon Institute researchers, working with young, healthy, South African women, found that individuals ...

Vaginal estriol gel helps women recover after surgery for pelvic organ prolapse

March 29, 2017
Pelvic organ prolapse is estimated to affect up to one-half of all women, causing pain and interfering with sexual function. A new study demonstrates how an ultralow dose of vaginal estriol gel used before and after pelvic ...

Abnormal pap posthysterectomy for 30 percent of HIV+ women

June 14, 2016
(HealthDay)—About one-in-three HIV-infected women with no prehysterectomy history of abnormal Pap results have abnormal vaginal Pap results after hysterectomy, according to a study published in the July issue of Obstetrics ...

Recommended for you

Unlocking the secrets of HIV's persistence

May 22, 2018
Thanks to advances in the development of anti-retroviral therapy (ART), patients with HIV are living longer than ever before. And yet, even in patients on very effective, long-term ART, HIV persists, requiring patients to ...

Discovery of how HIV hedges its bets opens the door to new therapies

May 10, 2018
A stem cell is one with infinite possibilities. So, for decades, scientists have puzzled over how the cell chooses to keep being a stem cell and continue dividing, or specialize into a specific cell type, like a heart or ...

Researchers find link between crystal methamphetamine and immune changes in HIV

May 4, 2018
A researcher at the University of Miami Miller School of Medicine has found that the use of stimulants, such as methamphetamine, can negatively affect the health of HIV-positive persons even when they are adhering to medical ...

Study challenges 'shock and kill' approach to eliminating HIV

May 1, 2018
Researchers have provided new insight into the cellular processes behind the 'shock and kill' approach to curing HIV, which they say challenges the effectiveness of the treatment.

State-of-the-art HIV drug could curb HIV transmission, improve survival in India

April 30, 2018
An HIV treatment regimen already widely used in North America and Europe would likely increase the life expectancy of people living with HIV in India by nearly three years and reduce the number of new HIV infections by 23 ...

Risks to babies of mothers with HIV from three antiretroviral regimens appear to be low

April 25, 2018
The risk for preterm birth and early infant death is similar for three antiretroviral drug regimens taken by pregnant women with HIV according to a new study from Harvard T.H. Chan School of Public Health.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.